Harbour BioMed – Talk Bio

Actionable Insights Powered by AI

Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

1 month ago talkbio0Tagged biobucks, Burning Mouth Syndrome, China, Clinical Trials, global strategic collaboration, Harbour BioMed, Harbour Mice ® technology, Immunology, License Agreement, milestones, multi-specific antibodies, Myers Squibb, Neoplasms

Harbour BioMed; Bristol Myers Squibb; BMS; multi-specific antibodies; $90 million upfront; $1.035 billion milestones; global strategic collaboration; license agreement; Harbour Mice technology; immunology; oncology; biobucks deal; China early clinical trials

Harbour BioMed Launches Élancé Therapeutics to Develop Next-Generation Obesity Treatments

11 months ago talkbio0Tagged bispecific antibody technology, Élancé, Harbour BioMed, next-generation, Obesity

Harbour BioMed, Élancé Therapeutics, Obesity therapies, Bispecific antibody technology, Next-generation treatments